GENEART is again Recognized as a German Top-Flight "Technology Fast
50" Company
- GENEART AG among the top 30 fastest growing technology companies in
Germany for the third time running
- 2nd rank among life science companies
- Cumulative growth by more than 500 percent in the last five years
- Synthetic genes mature from niche market product to standard
applications
Regensburg, October 11, 2007 - The GENEART AG with its above average
sales growth ranks 21st among the fastest growing German technology
companies in the "Technology Fast 50" competition. Creator and
organizer of the competition is the auditing and advisory services
firm Deloitte. Yesterday evening, the 50 winners of the prize for the
fastest growing technology enterprises showcased their business in
Frankfurt (Germany). The competition was attended by German
technology companies from business sectors including communications/
networking, the Internet, semiconductors/ equipment, computers/
peripherals, the life sciences and software. The placements are based
on the cumulative sales growth in percent for the preceding
consecutive five years.
The publicly traded GENEART AG as the global leader in the production
of synthetic genes and synthetic biology specialist grew its sales by
more than 500 percent to EURO 7.8M in this five-year period,
achieving one of the best placements among German companies together
with Q-Cells, QSC and proventis. Among life science companies GENEART
ranks 2nd in the competition.
"Step by step, the synthetic gene technology has gained wide market
acceptance. Clearly, the production of synthetic genes in general and
the GENEART technology platform for gene synthesis in particular have
well surpassed the traditional methods in molecular biology, and the
new procedures have cleared the way to a much faster and more
cost-effective access to genes, the blueprints of life. The use of
these genes can drastically shorten the development times for many
drugs, vaccines or industrial enzymes. Moreover, our technology
platform offers our customers unlimited design flexibilities and thus
supports researchers in their quest for products with improved
attributes", points out Professor Ralf Wagner, CSO of the GENEART AG.
Background: In the past, scientists had to spent months of hard work
in the laboratory to e.g. isolate a gene from a virus for their R&D
projects. The GENEART technology eliminates the above described work.
GENEART needs nothing but the electronic gene sequence information to
synthesize the desired gene in just a few days. This turns the
GENEART technology into a crucial advantage, especially in light of
the modern methods of sequencing and analyzing genes, which have
already produced a formidable wealth of known gene sequences, as
demonstrated by the genome project HUGO (Human Genome Organization).
This treasure box of information used to be of only limited use,
since it remained difficult to get a handle on the real gene
sequences using only the conventional tools of molecular biology. In
the last ten years, this has created an ever widening gap between
conventionally isolated genes and the rapidly accumulating wealth of
available gene sequence information. GENEART closes this gap with new
industrial processes for the production of genes based solely on
electronically available sequence information. This production of
defined synthetic genes is not only fast but also cost-efficient.
Other Advantages: GENEART has developed proprietary software to
visualize the targeted modification of gene sequences on a computer
monitor, much like changing images using a Photoshop program. This
enables scientists to optimize genes for a specific design goal. The
benefits for the customer include improved product attributes, higher
production rates, enhanced efficacies and lower production costs.
"Meanwhile, many companies and research institutes have recognized
the benefits of the GENEART services. Almost all of the largest
global pharmaceutical companies, many international biotechnology
companies, renowned universities and large research facilities now
use the GENEART technology platform", notes Christian Ehl, CFO of the
GENEART AG.
For further inquiries, please contact:
Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
D-93053 Regensburg
Germany
Phone: +49-(0)941-942 76 - 638
Fax: +49-(0)941-942 76 - 711
ir@geneart.com
www.geneart.com
Legal Information
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the synthetic biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001-2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. The GENEART
AG in Regensburg (Germany) and the subsidiary GENEART Inc. in Toronto
(Canada) employ more than 140 people. Since May 2006, GENEART is
listed on the German Stock Exchange.
About Deloitte in Germany
Deloitte is one of the leading auditing and consulting firms in
Germany. The firm's broad service spectrum includes auditing, tax
accounting, consulting and corporate finance consulting. 3,400
Deloitte employees in 18 branch offices serve companies and
institutions of any size or legal form in all sectors of the economy.
Deloitte looks back at almost 100 years of service history. 135,000
employees in almost 150 countries on the globe represent Deloitte via
the Deloitte Touche Tohmatsu network.
Deloitte refers to Deloitte Touche Tohmatsu, an association formed
according to the Swiss Civil Code, and its member companies including
the affiliates of these member companies. Neither Deloitte Touche
Tohmatsu as an association under the Swiss Civil Code nor its member
companies are liable or responsible for each other's actions or
omissions. Each member company is a legally separate and independent
entity, whether or not it operates under the names "Deloitte",
"Deloitte & Touche", "Deloitte Touche Tohmatsu" or another name
associated with the aforementioned names. Services are rendered by
each of the individual member companies and not by the Association
Deloitte Touche Tohmatsu. Copyright © 2006 Deloitte & Touche GmbH
Wirtschaftsprüfungsgesellschaft (Deloitte & Touche GmbH [LLC
according to Swiss law], Auditing Firm). All rights reserved.
